1Department of Oncology, The First Hospital Affiliated to Guangzhou University of Chinese Medicine, China 2Department of Chinese Medicine, Naval Medical University, ChinaFulltext PDF
Neoantigen mRNA vaccines are a potential form of immunotherapy for Hepatocellular Carcinoma (HCC), a type of liver cancer. Neoantigens are unique protein fragments that are generated by mutations in cancer cells, and are not present in normal cells. These neoantigens can be targeted with personalized mRNA vaccines, which are designed to stimulate the patient's immune system to recognize and destroy cancer cells. In HCC, neoantigen mRNA vaccines are developed using RNA sequences that are synthesized based on the genetic mutations found in a patient's tumor. These RNA sequences are formulated into a vaccine and administered to the patient, typically in combination with other cancer treatments. Once administered, the vaccine enters the patient's cells and instructs them to produce the neoantigens, which are then presented to the immune system as foreign and targeted for destruction. Several preclinical and clinical studies have shown promising results for neoantigen mRNA vaccines in HCC immunotherapy. Early results suggest that they may be a valuable addition to the treatment options available for HCC patients. However, more research is needed to determine the safety and efficacy of these vaccines.
mRNA vaccine; Immunotherapy; Cancer treatment
Han R. Selecting mRNA Vaccine that can Improve the Efficacy of Immunotherapy for Liver Cancer Treatment. Open J Public Health. 2023; 5(1): 1045..